US20170258844A1 - Pluripotent stem cell for treating diabetic skin ulcer - Google Patents

Pluripotent stem cell for treating diabetic skin ulcer Download PDF

Info

Publication number
US20170258844A1
US20170258844A1 US15/508,872 US201515508872A US2017258844A1 US 20170258844 A1 US20170258844 A1 US 20170258844A1 US 201515508872 A US201515508872 A US 201515508872A US 2017258844 A1 US2017258844 A1 US 2017258844A1
Authority
US
United States
Prior art keywords
cells
negative
pluripotent stem
cell preparation
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/508,872
Other languages
English (en)
Inventor
Kotaro Yoshimura
Kahori Kinoshita
Mari Dezawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
University of Tokyo NUC
Original Assignee
Tohoku University NUC
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University NUC, University of Tokyo NUC filed Critical Tohoku University NUC
Assigned to THE UNIVERSITY OF TOKYO, TOHOKU UNIVERSITY reassignment THE UNIVERSITY OF TOKYO ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KINOSHITA, Kahori, YOSHIMURA, KOTARO, DEZAWA, MARI
Publication of US20170258844A1 publication Critical patent/US20170258844A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to a cell preparation for use in regenerative medicine. More particularly, the present invention relates to a cell preparation comprising pluripotent stem cells effective for repair and regeneration of skin tissue in skin ulcers including skin ulcers caused by diabetes, and to a method for treating skin ulcers that uses these pluripotent stem cells.
  • Diabetes is a disease that is associated with persistent hyperglycemic state and is said to occur as a result of the actions of a diverse range of environmental and genetic factors.
  • the main regulatory factor of blood sugar is insulin, and hyperglycemia is known to occur due to insulin deficiency or an excess of factors that inhibit the action thereof (such as genetic predisposition, lack of exercise, obesity or stress).
  • Diabetes is classified as type 1 diabetes, which occurs primarily due to a decrease in pancreatic insulin secretory function attributable to such factors as autoimmune diseases, and type 2 diabetes, which is caused by a decrease in pancreatic insulin secretory function or insulin resistance caused by pancreatic exhaustion associated with persistently high levels of insulin secretion.
  • Non-Patent Document 1 the global market for antidiabetic drugs is on the order of roughly 1 trillion yen. This makes diabetes the top-ranked disease both in terms of market size and population.
  • Atherosclerosis Similar to large vessel disease, patients with diabetes are at greater risk to skin perfusion associated with non-conductive arteries during the course of impairment of the microcirculation control mechanism referred to as atherosclerosis or microvascular disease. Under normal circumstances, blood flow increases in order to promote healing in response to injury. However, in cases in which microvascular disease (or ischemia) is present, this response is significantly impaired, and this is considered to most likely be important in the etiology of ulcers together with a tendency towards the occurrence of thrombosis in the microcirculation during reduced blood flow.
  • nerve disorders lack an adequately established treatment method with respect to both the symptomatic treatment thereof and the prevention of the progressive decline of nerve function, and is one of the major complications of diabetes mellitus. The effects of peripheral nerve disorders are particularly complex. Although the mechanism leading to nerve damage associated with diabetes has yet to be fully understood, it is said to involve multiple factors, such as genetic predisposition, metabolic and vascular abnormalities or a lack of perturbation of related growth factors.
  • Adipose tissue-derived stromal cells are known to be one type of such cells, and are thought to have the ability to differentiate into not only adipocytes and blood vessels, but also various other tissue cells and tissue lines (Non-Patent Documents 2 to 4).
  • ASC Adipose tissue-derived stromal cells
  • An attempt to treat ischemic injury by producing diabetic mice has been reported as an example of the use of ASC (Non-Patent Document 5).
  • an example of applying adipose-derived regenerative cells to the clinical treatment of diabetic ulcers of the lower extremities of patients afflicted with peripheral arterial diseases has also been reported (Non-Patent Document 6).
  • these attempts have not led to complete recovery at the injured site.
  • MSC mesenchymal stem cells
  • adipocytes adipocytes, nerve cells or skeletal muscle and the like
  • these constitute a cell population that includes various cells, the actual state of that differentiation ability is not fully understood, and there have been considerable variations in the therapeutic effects thereof.
  • iPS cells have been reported to be adult-derived pluripotent stem cells (as reported in Patent Document 1, for example), in addition to the establishment of iPS cells requiring an extremely complex procedure consisting of introducing a specific gene into mesenchymal cells in the form of skin fibroblasts or introducing a specific compound into somatic cells, iPS cells are also highly tumorigenic, thereby resulting in the presence of extremely difficult obstacles to their clinical application.
  • pluripotent stem cells present in a mesenchymal cell fraction that express a surface antigen in the form of stage-specific embryonic antigen-3 (SSEA-3) (referred to as multilineage-differentiating stress enduring cells (Muse cells)) are responsible for the pluripotency of that mesenchymal cell fraction, and were determined to have the potential to be applied to disease treatment targeted at tissue regeneration (Patent Document 2, Non-Patent Documents 9 to 12).
  • SSEA-3 stage-specific embryonic antigen-3
  • Muse cells multilineage-differentiating stress enduring cells
  • Patent Document 1 Japanese Patent No. 4183742
  • Patent Document 2 International Publication No. WO 2011/007900
  • Non-Patent Document 1 Stumvoll, M., et al., Lancet, Vol. 365, p. 1333-1346 (2005)
  • Non-Patent Document 2 Rehman, J., et al., Circulation, Vol. 109, p. 1292-1298 (2004)
  • Non-Patent Document 3 Planat-Benard, V., et al., Circulation, Vol. 109, p. 656-663 (2004)
  • Non-Patent Document 4 Miranvile, A., et al., Circulation, Vol. 110, p. 349-355 (2004)
  • Non-Patent Document 5 Kim, E. K., et al., Plast. Reconstr. Surg., Vol. 128, p. 387-394 (2011)
  • Non-Patent Document 6 Marino, G., et al., J. Surg. Res., Vol. 185, p. 36-44 (2013)
  • Non-Patent Document 7 Dezawa, M., et al., J. Clin. Invest., Vol. 113, p. 1701-1710 (2004)
  • Non-Patent Document 8 Dezawa, M., et al., Science, Vol. 309, p. 314-317 (2005)
  • Non-Patent Document 9 Li, S., et al., Cancer Gene Therapy, Vol. 12, p. 600-607 (2005)
  • Non-Patent Document 10 Kuroda, Y., et al., Proc. Natl. Acad. Sci. USA, Vol. 107, p. 8639-8643 (2010)
  • Non-Patent Document 11 Wakao, S., et al., Proc. Natl. Acad. Sci. USA, Vol. 108, p. 9875-9880 (2011)
  • Non-Patent Document 12 Kuroda, Y., et al., Nat. Protoco., Vol. 8, p. 1391-1415 (2013)
  • An object of the present invention is to provide a novel medical application using pluripotent stem cells (Muse cells). More specifically, an object of the present invention is to provide a cell preparation for the prevention and/or treatment of skin ulcers that contains Muse cells.
  • the inventors of the present invention found that, by administering Muse cells to mice with diabetic skin ulcer, the Muse cells are able to reconstruct and repair skin tissue that results in healing of the ulcer, thereby leading to completion of the present invention.
  • a cell preparation for preventing and/or treating skin ulcer comprising pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells.
  • pluripotent stem cells are CD34-negative, CD117-negative, CD146-negative, CD271-negative, NG2-negative, vWF-negative, Sox10-negative, Snail-negative, Slug-negative, Tryp1-negative and Dct-negative.
  • pluripotent stem cells are pluripotent stem cells having all of the following properties:
  • pluripotent stem cells have the ability to differentiate into one or more cells selected from the group consisting of epidermal keratinocytes, vascular endothelial cells, vascular pericytes, adipocytes, preadipocytes, skin fibroblasts and nerve sheath cells.
  • the present invention is able to inhibit the progression of skin ulcer and repair skin tissue by a skin tissue regeneration mechanism by which Muse cells differentiate into cells that constitute skin tissue at the site of a skin ulcer following administration of the Muse cells to that site in a subject afflicted with skin ulcer.
  • FIG. 1A Since mice typically have an inherently high level of wound healing ability that enables wounds to heal rapidly, it is difficult to clearly differentiate differences in wound healing when evaluating the wound healing effect of a drug. Consequently, immunodeficient mice afflicted with diabetes, which is characterized by impaired progression of wound healing, were used to evaluate wound healing effects.
  • 5-week-old female SCID mice were intraperitoneally injected with streptozotocin (STZ) after fasting for 24 hours.
  • the mice were investigated for hyperglycemia (blood glucose >300 mg/dl) 3 days after administration of STZ (150 mg/kg). Administration of STZ (150 mg/kg) was repeated in the case hyperglycemia was not observed.
  • FIG. 1B indicates typical changes in blood sugar levels. Nearly all of the mice became hyperglycemic after one or two injections of STZ.
  • FIG. 2 MSC are known secrete a growth factor required during the inflammatory phase and cell growth phase of wound healing. Therefore, the relative values of growth factor production in Muse cell fractions and mesenchymal cell fractions (MSC) cultured for 48 hours under hypoxic (1% O 2 ) and normoxic conditions were measured by ELISA.
  • the measured cytokines consisted of HGF, SDF-1, PDGF-BB, VEGF, EGF, TGF- ⁇ , NGF- ⁇ , bFGF and TNF- ⁇ .
  • Asterisks (*) indicate P ⁇ 0.05.
  • FIG. 3 Wound healing of skin defects (diameter: 6 mm) were sequentially evaluated through day 14. The wounds were photographed and the ratio (%) of the wound area to the original size of the wound was calculated using digital image analysis software. Although wound healing was observed to be somewhat slower in the SCID mice in comparison with wild-type mice (WT), wound healing in the STZ-induced DM-SCID mice was impaired to a greater extent than in the SCID mice. Wound closure was significantly faster in the DM-SCID mice treated with the Muse cell population than untreated DM-SCID mice, and these mice demonstrated favorable wound healing in comparison with the DM-SCID mice treated with MSC (* P ⁇ 0.05).
  • FIG. 4 This indicates the results of an analysis of human Golgi complex in the wounds of DM-SCID mice treated with Muse cells and MSC.
  • Cells positive for human Golgi complex (comparable to transplanted Muse cells) were observed in the epidermis and upper layer of both wound areas treated with Muse cells and MSC after 14 days.
  • cells positive for human Golgi complex were not detected in either group in surrounding undamaged areas.
  • Transplanted human cells were detected at a higher frequency in the Muse cell treated samples than in the MSC treated samples.
  • FIG. 5 Human Golgi complex and a differentiation marker (PECAN-1) were subjected to double immunohistochemical staining in order to characterize transplanted Muse cells. Several cells that expressed human Golgi complex were suggested to differentiate into vascular endothelial cells in the dermis since they were positive for PECAM-1.
  • the present invention relates to a cell preparation for preventing and/or treating skin ulcer that comprises SSEA-3-positive pluripotent stem cells (Muse cells).
  • SSEA-3-positive pluripotent stem cells Mal cells
  • the present invention aims to prevent and/or treat skin ulcer by using a cell preparation comprising SSEA-3-positive pluripotent stem cells (Muse cells).
  • skin ulcer refers to damage to the skin normally caused by a defect (exposure of the dermis or subcutaneous tissue) of the tissue surface caused by inflammation.
  • skin ulcers include diabetic skin ulcer, decubitus ulcer, venous stasis ulcer, arterial ulcer, radiation ulcer, necrotizing fasciitis and third degree burns.
  • Diabetic skin ulcer refers to an extremely refractory skin ulcer caused by damage to vascular endothelial cells attributable to diabetes, and examples thereof include diabetic foot ulcers and diabetic lower leg ulcers.
  • Decubitus refers to a chronic ulcer caused by pressure applied over an extended period of time to an area of skin. This type of ulcer is frequently referred to as a bedsore.
  • Vehicle stasis ulcer occurs due to congestion of blood or other fluid from a defective vein.
  • Arterial ulcer refers to necrotic skin in an area surrounded by arteries having poor circulation.
  • Rapid ulcer indicates an ulcer occurring in irradiated skin.
  • “Necrotizing fasciitis” indicates a soft tissue inflammation that begins with bacterial infection of superficial fascia followed by the rapid spread of necrosis.
  • “third degree burns” refers to burns extending to the full thickness of the dermal layer and subcutaneous tissue.
  • the cell preparation of the present invention is effective for preventing and/or treating diabetic skin ulcer in particular.
  • Muse cells can be obtained from bone marrow, adipocytes (Ogura, F., et al., Stem Cells Dev., Vol. 23, p. 717-728 (2014)) and skin tissue such as dermal connective tissue, and are also sporadically present in the connective tissue of various organs.
  • Muse cells or cell populations containing Muse cells can be isolated from body tissue by using these antigen markers as indicators.
  • cell populations containing Muse cells can be concentrated by long-term exposure to stress caused by hypoxia or proteases such as trypsin or dispase. Details regarding the isolation, identification and characteristics of Muse cells are disclosed in International Publication No. WO 2011/007900. In addition, as was reported by Wakao, et al.
  • Muse cells in the case of culturing mesenchymal cells from bone marrow or skin and the like and using those cells as a Muse cell parent population, all SSEA-3-positive cells were determined to be CD105-positive cells.
  • Muse cells in the case of isolating Muse cells from the mesenchymal tissue of a body or cultured mesenchymal cells, Muse cells can be purified and used by simply using SSEA-3 as an antigen marker.
  • pluripotent stem cells or a cell population containing Muse cells that has been isolated from the mesenchymal tissue of a body or cultured mesenchymal cells by using SSEA-3 as an antigen marker may simply be described as “SSEA-3-positive cells”.
  • Muse cells or cell populations containing Muse cells can be isolated from body tissue (such as mesenchymal tissue) by using only antibody to a cell surface marker in the form of SSEA-3 or by using antibodies to both SSEA-3 and CD105.
  • a “body” refers to the body of a mammal. In the present invention, a body does not include fertilized eggs or embryos in an earlier stage of development than the blastocyst stage, but includes fetuses and embryos in a stage of development beyond the blastocyst stage including blastula.
  • mammals include, but are not limited to, primates such as humans or monkeys, rodents such as mice, rats, rabbits or guinea pigs, as well as cats, dogs, sheep, pigs, cows, horses, donkeys, goats and ferrets.
  • the Muse cells used in the cell preparation of the present invention are clearly distinguished from embryonic stem (ES) cells and iPS cells in that they are isolated directly from the body by means of a marker.
  • ES embryonic stem
  • iPS cells in that they are isolated directly from the body by means of a marker.
  • meenchymal tissue refers to tissue present in tissue or various organs such as bone, periosteum, blood, bone marrow, skeletal muscle, dermis, ligaments, tendons, dental pulp, umbilical cord or umbilical cord blood.
  • Muse cells can be obtained from bone marrow, skin and adipose tissue. Muse cells are preferably used, for example, by collecting mesenchymal tissue from a body and isolating Muse cells from this tissue. In addition, Muse cells may also be isolated from cultured mesenchymal cells such as fibroblasts or bone marrow mesenchymal stem cells using the aforementioned isolation means. Furthermore, Muse cells used in the cell preparation of the present invention may be autologous or heterologous with respect to the recipient of a cell transplant.
  • Muse cells or cell populations containing Muse cells can be isolated from body tissue by being positive for SSEA-3 indicator or being double positive for SSEA-3 and CD105 indicators
  • various types of stem cells and precursor cells are known to be contained in human adult skin.
  • Muse cells are not the same as these cells.
  • Examples of these stem cells and precursor cells include skin-derived precursor cells (SKP), nerve cell stem cells (NCSC), melanoblasts (MB), perivascular cells (PC), endothelial precursor cells (EP) and adipose-derived stem cells (ADSC).
  • Muse cells can be isolated by using “non-expression” of markers unique to these cells as an indicator.
  • Muse cells can be isolated by using as an indicator the non-expression of at least 1, and for example, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 markers selected from the group consisting of CD34 (marker for EP and ADSC), CD117 (c-kit) (marker for MB), CD146 (marker for PC and ADSC), CD271 (NGFR) (marker for NCSC), NG2 (marker for PC), vWF factor (von Willebrand factor) (marker for EP), Sox10 (marker for NCSC), Snail (marker for SKP), Slug (marker for SKP), Tyrp1 (marker for MB) and Dct (marker for MB).
  • CD34 marker for EP and ADSC
  • CD117 c-kit
  • CD146 marker for PC and ADSC
  • CD271 (NGFR) marker for NCSC
  • NG2 marker for PC
  • vWF factor von Willebrand factor
  • Sox10 marker for NCSC
  • Snail marker for SKP
  • Muse cells can be isolated by using non-expression of CD117 and CD146, non-expression of CD117, CD146, NG2, CD34 vWF and CD271, or using non-expression of the aforementioned 11 markers as an indicator.
  • Muse cells having the aforementioned characteristics used in the cell preparation of the present invention may have at least one property selected from the group consisting of:
  • Muse cells used in the cell preparation of the present invention have all of the aforementioned properties.
  • the “low or absent telomerase activity” of i) refers to having low telomerase activity or being unable to detect telomerase activity in the case of attempting to detect telomerase activity using, for example, the Trapeze XL Telomerase Detection Kit (Millipore).
  • Low telomerase activity refers to having telomerase activity roughly equal to that of somatic cells in the form of human fibroblasts or having telomerase activity equal to 1 ⁇ 5 or less and preferably 1/10 or less that of Hela cells.
  • the Muse cells referred to in ii) have the ability to differentiate into the three germ layers (endoderm, mesoderm and ectoderm) in vitro and in vivo, and are able to differentiate into, for example, liver cells, nerve cells, skeletal muscle cells, smooth muscle cells, osteocytes or adipocytes by subjecting to culturing to induce differentiation in vitro.
  • they may also demonstrate the ability to differentiate into the three germ layers in vivo in the case of transplanting to the testes.
  • they also have the ability to migrate to and become established in damaged organs (such as the heart, skin, spinal cord, liver or muscle) and subsequently differentiate into cells corresponding to that tissue by being transplanted into the body by intravenous injection.
  • the Muse cells referred to in iii) have the property of proliferating at a growth rate of about 1.3 days during suspension culturing, and discontinuing to grow after about 14 days after growing from a single cell and forming an embryoid body-like cell mass during suspension culturing, when these embryoid body-like cell masses are subjected to adherent culturing, cell growth resumes and cells that have grown from the cell masses begin to disseminate.
  • these Muse cells also have the property of not undergoing malignant transformation for at least six months in the case of having transplanted into the testes.
  • the Muse cells referred to in iv) have the ability to undergo self-renewal.
  • self-renewal refers to being able to confirm differentiation into tridermic cells from cells contained in am embryoid body-like cell mass obtained by culturing in a suspension culture starting from a single Muse cell, while at the same time being able to again confirm tridermic differentiation and embryoid body-like cell masses during suspension culturing following the formation of next-generation embryoid body-like cell masses by again subjecting cells of the embryoid body-like cell mass to suspension culturing.
  • Self-renewal may be repeated for a single cycle or a plurality of cycles.
  • the cell preparation of the present invention is obtained by suspending the Muse cells or cell population containing Muse cells obtained in the aforementioned section (1) in physiological saline or a suitable buffer (such as phosphate-buffered physiological saline).
  • physiological saline or a suitable buffer such as phosphate-buffered physiological saline.
  • the cells may be cultured prior to transplant to increase the number of cells until the prescribed cell density is obtained.
  • Muse cells do not undergo neoplastic transformation as was previously reported (International Publication No. WO 2011/007900), the possibility of undergoing malignant transformation is low, thereby making these cells safe even if cells recovered from body tissue are contained while still in an undifferentiated state.
  • the recovered Muse cells can be cultured in ordinary growth medium (such as a-minimum essential medium ( ⁇ -MEM) containing 10% calf serum). More specifically, during culturing and proliferation of Muse cells with reference to the aforementioned International Publication No. WO 2011/007900, a solution containing a prescribed Muse cell density can be prepared by suitably selecting the medium and additives (such as antibiotic or serum).
  • a solution containing a prescribed Muse cell density can be prepared by suitably selecting the medium and additives (such as antibiotic or serum).
  • the Muse cells can be isolated using an antigen marker in the form of SSEA-3 as an indicator to prepare a solution containing Muse cells at a prescribed density.
  • Muse cells can be prepared in the form of a cell preparation by concentrating a cell population containing Muse cells by exposing to stress caused by hypoxia or protease.
  • autologous Muse cells can be prepared in the form of a cell preparation by isolating Muse cells using SSEA-3 antigen marker as an indicator followed by increasing the number of cells by culturing until a prescribed therapeutic amount is reached.
  • DMSO dimethylsulfoxide
  • serum albumin and the like may be contained in the cell preparation to protect the cells and antibiotic may be contained to prevent contamination and growth of bacteria.
  • other pharmaceutically acceptable components such as a carrier, excipient, disintegrating agent, buffer, emulsifier, suspending agent, soothing agent, stabilizer, preservative, antiseptic or physiological saline
  • cells or components other than Muse cells contained in mesenchymal stem cells may also be contained in the cell preparation.
  • a person with ordinary skill in the art is able to add these factors and drugs to the cell preparation at suitable concentrations thereof. In this manner, Muse cells can be used as a pharmaceutical composition containing various types of additives.
  • the number of Muse cells contained in the cell preparation prepared as described above can be suitably adjusted in consideration of such factors as the gender, age and body weight of the subject, status of the affected area or status of the cells used so as to obtain a desired effect when treating skin ulcer (such as reconstruction of skin tissue).
  • various effects of transplanting Muse cells were examined in an immunodeficient diabetic mouse model produced by administering streptozotocin (STZ). Extremely superior effects were obtained by administering SSEA-3-positive cells to SCID mice weighing approximately 20 g to 30 g at 1.0 ⁇ 10 5 cells/animal.
  • the cell preparation of the present invention may be administered a plurality of times (such as 2 to 10 times) at a suitable interval (such as twice a day, once a day, twice a week, once a week, once every two weeks, once a month, once every two months, once every three months or once every six months) until the desired therapeutic effect is obtained.
  • the therapeutically effective amount is preferably, for example, a dosage of 1 ⁇ 10 3 cells to 1 ⁇ 10 7 cells per individual administered 1 to 10 times.
  • the total administered dosage per individual include, but are not limited to, 1 ⁇ 10 3 cells to 1 ⁇ 10 8 cells, 1 ⁇ 10 4 cells to 5 ⁇ 10 7 cells, 2 ⁇ 10 4 cells to 2 ⁇ 10 7 cells, 5 ⁇ 10 4 cells to 5 ⁇ 10 6 cells and 1 ⁇ 10 5 cells to 1 ⁇ 10 6 cells.
  • a mouse diabetic skin ulcer model can be produced and used to examine the therapeutic effects of the cell preparation of the present invention on skin ulcer.
  • examples of mice used in this model typically include SCID mice and Balb/c mice.
  • the diabetic skin ulcer model can be produced by intraperitoneal administration of streptozotocin (STZ) to these mice.
  • STZ is a glucose derivative that damages ⁇ cells of the pancreas, and is used to cause the onset of diabetes in animals.
  • the dosage of STZ is preferably 150 mg/kg per administration and may be administered multiple times.
  • the cell preparation of the present invention comprises human-derived Muse cells
  • the cells are heterogeneous with respect to the mice administered the preparation.
  • an immunosuppressant such as cyclosporine
  • an immunosuppressant is administered prior or simultaneous to administration of the heterologous cells in order to suppress rejection of the heterologous cells in the body.
  • the inventors of the present invention previously found that a Muse cell parent population in the form of mesenchymal cells inherently demonstrates potent immunosuppression and that
  • Muse cells also demonstrate a similar action.
  • the use of an immunosuppressant is not required in a mouse model other than SCID mice in which an immunosuppressant is not used.
  • the cell preparation of the present invention is able to reconstruct normal tissue by treating skin ulcer of a patient.
  • “reconstructing normal tissue” refers to an affected area having a skin ulcer being completely treated as a result of healing the wound.
  • the state of the reconstructed skin is preferably such that the surface thereof is completely covered with epidermal keratinocytes and epithelization has been completed.
  • dermis of an adequate thickness is more preferably constructed beneath the epidermis. Even more preferably, skin appendages such as sweat glands and/or hair follicles are additionally regenerated.
  • various cytokines can be made to be secreted from the Muse cells by culturing the Muse cells in a hypoxic state (such as at an oxygen concentration of 1%) (see Example 3).
  • a method is provided for increasing production capacity of at least one cytokine among VEGF, EGF, PDGF-BB, NGF- ⁇ , SCF, TNF- ⁇ , bFGF and TGF- ⁇ .
  • adipose tissue was washed with PBS and digested in PBS containing 0.075% collagenase for 30 minutes at 37° C. on a shaker. Mature adipocytes and connective tissue were separated from the pellet by centrifugal separation. The cell pellet was then re-suspended and lysed by passing through 100 ⁇ m, 70 ⁇ m and 40 ⁇ m screens.
  • the cell pellet containing adipose-derived stromal/stem cells (ASC) (equivalent to SVF) was cultured in a culture dish containing Dulbecco's Modified Eagle's Medium (DMEM, Nissui, Tokyo, Japan) enriched with 10% fetal bovine serum (FBS).
  • DMEM Dulbecco's Modified Eagle's Medium
  • the ASC that proliferated about 2 weeks after culturing were sub-cultured using the same medium.
  • the second generation of sub-cultured hASC were recovered over the course of 5 minutes at 37° C. using 0.25% trypsin containing 2 mM EDTA and then used to isolate Muse cells.
  • a magnetic-activated cell sorter (MACS, autoMACS, Miltenyl Biotec, Bergisch Gladbach, Germany) was used to recover SSEA-3-positive Muse cells. Since Muse cells expressed SSEA-3 on the surface thereof, anti-SSEA-3 antibody coupled to phycoerythrin (PE, 1:3 dilution, Miltenyl Biotec) and anti-PE microbeads (1:2 dilution, Miltenyl Biotec) were used for MACS isolation of the Muse cells. Target cells labeled with microbeads were trapped in the magnetic field followed by recovery in the form of a positive fraction. The cell solution that did not bind to the magnetic column was recovered in the form of a negative fraction.
  • PE phycoerythrin
  • anti-PE microbeads (1:2 dilution, Miltenyl Biotec
  • a MACS program was used in which the cell solution was applied twice to the magnetic column at an extremely slow speed in order to more favorably purify the Muse cells.
  • the resulting positive cell fraction was used in the following examples as a Muse cell population, while the negative cell fraction was used as mesenchymal cell fraction (MSC).
  • SCID mice Five-week-old severe combined immunodeficient (SCID) mice (C. B17/Icr-scid scid/scid) were purchased from Clea Japan, Inc. (Tokyo, Japan). All animal experiments were carried out with the approval of the Institutional Animal Care and Use Committee of the University of Tokyo. After allowing the SCID mice to fast for 24 hours, the animals were intraperitoneally injected with freshly prepared citrate-buffered saline (pH 4.5) containing streptozotocin (STZ, 150 mg/kg, Sigma-Aldrich, St. Louis Mo.).
  • Blood glucose levels were measured using a glucometer and test strips (Glucose Pilot, Aventir Biotech LLC, Carlsbad, Calif.) on the third day after injection of STZ. Mice were considered to have diabetes mellitus (DM) if blood glucose level exceeded 300 mg/dl. Those mice that did not exhibit hyperglycemia (blood glucose level in excess of 300 mg/dl) were subjected to a second round of STZ injection (150 mg/kg) followed by monitoring blood glucose levels three days later.
  • DM diabetes mellitus
  • Skin defects were produced on the backs of the mice as previously described (see Galiano, R. D., et al., Wound Repair Regen., Vol. 12, p. 485-492 (2004) and Tepper, O. M., Diabetes, Vol. 10, 2337/db09-0185) in order to evaluate healing of skin wounds. More specifically, each mouse was anesthetized by intraperitoneal injection of pentobarbital (65 mg/kg). After shaving the backs of the animals with an electric trimmer and depilatory cream, two full-thickness skin wounds (diameter: 6 mm) penetrating to the dermomuscular layer were produced on the backs of the mice using a sterilized circular biopsy punch (Kai Industries Co., Tokyo, Japan).
  • a doughnut-shaped silicon splint (silicon rubber sheet having an inner diameter of 9 mm, outer diameter of 15 mm and thickness of 1.0 mm, Kyowa Industries, Saitama, Japan) was placed on the wounds and fixed in position using 6-0 nylon suture to avoid contraction of the wound ( FIG. 1A ).
  • An occlusive bandage (Perme-roll, Nitto Medical, Osaka, Japan) was used to prevent the wound from drying and forming a scab.
  • mice Five experimental groups were prepared consisting of wild-type mice, non-DM-SCID mice, DM-induced SCID mice, DM-induced SCID mice treated with the Muse cell population, and DM-induced SCID mice treated with the mesenchymal cell fraction (MSC). Six mice were used in each group. Muse cells (1.0 ⁇ 10 5 cells/mouse) were mixed with 0.1 ml of crosslinked hyaluronic acid (Restylane, Q-MED, Uppsala, Sweden) followed by injecting subcutaneously around the wounds. The amount of time until wound closure (number of days until complete epidermal regeneration) was investigated macroscopically. The wounds were sequentially photographed on days 0, 3, 7, 10 and 14 using an ordinary digital camera (IXY Digital 90, Canon, Tokyo, Japan). The photographs were evaluated using image analysis software (Photoshop CS6, Adobe Systems, San Jose, Calif.) followed by measurement of wound area.
  • image analysis software Photoshop CS6, Adobe Systems, San Jose, Calif.
  • MSC are known to secrete growth factors (such as PDGF, bFGF, TGF- ⁇ or EGF) required in the inflammatory phase and cell growth phase of wound healing (Maxson, S., et al., Stem Cells Transl. Med., Vol. 1, p. 142-149 (2012)). Therefore, the Muse cell population and MSC were cultured in vitro under hypoxic and normoxic conditions to examine cytokines secreted into the culture broth. The experiment was carried out in the manner indicated below. 4.0 ⁇ 10 5 cells of the Muse cell population and MSC were disseminated in a 60 mm culture dish followed by culturing in serum-free DMEM under hypoxic (1% O 2 ) and normoxic (6% O 2 ) conditions.
  • growth factors such as PDGF, bFGF, TGF- ⁇ or EGF
  • the culture medium was recovered 48 hours later and filtered using a 0.22 ⁇ m filter (Millex-GV Filter, Millipore, Billerica, Mass.).
  • HGF hepatocyte growth factor
  • SDF-1 stromal cell-derived factor 1
  • VEGF vascular endothelial growth factor
  • EGF epidermal growth factor
  • PDGF-BB platelet-derived growth factor
  • NGF- ⁇ nerve growth factor- ⁇
  • SCF steam cell factor
  • TGF- ⁇ tumor necrosis factor- ⁇
  • TGF- ⁇ basic fibroblast growth factor
  • TGF- ⁇ transforming growth factor- ⁇
  • Absorbance was measured at 450 nm by spectrophotometry using an Infinite microplate reader (M1000, Tecan
  • the results of adherent culturing of the Muse cell population and MSC under normoxic (6% O 2 ) and hypoxic (1% O 2 ) conditions and comparing the concentrations of cytokines present in the culture medium 48 hours later are shown in FIG. 2 .
  • the Larger amounts of EGF, PDGF-BB, NGF- ⁇ , SCF, TNF- ⁇ , bFGF and TGF- ⁇ were detected in the Muse cell population in comparison with MSC cultured at the same oxygen pressure.
  • the concentrations of VEGF, EGF, PDGF-BB, NGF- ⁇ , SCF, TNF- ⁇ , bFGF and TGF- ⁇ were higher in the Muse cell population under hypoxic conditions than the concentrations thereof under normoxic conditions.
  • DM-SCID mice also demonstrated larger wound sizes than the WT mice or non-DM-SCID mice on day 14.
  • the DM-SCID mice were confirmed to be an animal model of immunodeficiency associated with impaired wound healing.
  • the wound sizes on day 7 of the DM-SCID mice treated with Muse cells and MSC were 51.05 ⁇ 7.2% and 74.0 ⁇ 6.6%, respectively (P ⁇ 0.0001).
  • wound healing was accelerated and appeared to be comparable to that in the WT group.
  • Mouse skin samples were embedded in OCT compound (Sakura Finetek, Tokyo, Japan), frozen in liquid nitrogen and stored at ⁇ 80° C. until sectioned.
  • the frozen sections (8 ⁇ m) were placed on slides and allowed to dry for 20 minutes at room temperature followed by fixing for 1 minute with 4% paraformaldehyde (in PBS) and washing for 5 minutes with PBS.
  • the slides were then stained with hematoxylin and eosin (H&E) and treated for immunohistochemical analysis.
  • human 58K Golgi protein was visualized by a peroxidase reaction using 3,3′-diaminobenzidine tetrahydrochloride (DAB).
  • DAB 3,3′-diaminobenzidine tetrahydrochloride
  • the frozen sections were incubated with the following primary antibodies for observing with a confocal laser scanning microscope: mouse anti-human mitochondria (1:100 dilution, Abcam), rabbit anti-human 58K Golgi protein, rabbit anti-human CK14 (1:200 dilution, Abcam) or goat anti-human platelet endothelial cell adhesion molecule (PECAN-1, dilution: 1:50, Santa Cruz Biotechnology, Santa Cruz, Calif.).
  • PECAN-1 goat anti-human platelet endothelial cell adhesion molecule
  • the sections were incubated with the following secondary antibodies: donkey anti-mouse IgG-Alexa488, donkey anti-rabbit IgG-Alexa680 or rabbit anti-goat IgG-Alexa488 (all 1:500 dilutions, Invitrogen, Carlsbad, Calif.). Nuclei were counterstained with DAPI and examined using a confocal microscope (Clsi Nikon, Nikon, Tokyo, Japan).
  • transplanted cells were shown to be detected in the epidermis and upper dermal layer in each of the samples treated with the Muse cell population and MSC on day 14.
  • cells that expressed human Golgi complex were not observed in surrounding undamaged areas ( FIG. 4 ).
  • deposition of the injected hyaluronic acid was detected in the subcutaneous layer.
  • several cells that expressed human Golgi complex within the dermis were positive for h-PECAM-1 ( FIG. 5 ). This data suggests that transplanted Muse cells are viable in both the epidermis and dermis and are capable of differentiating into epidermal keratinocytes and vascular endothelial cells.
  • the cell preparation of the present invention is able to reconstruct and repair skin tissue by administering to an area affected by skin ulcer in a mouse model of diabetic skin ulcer, and can therefore be applied to the treatment of diabetic skin ulcer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US15/508,872 2014-09-05 2015-06-19 Pluripotent stem cell for treating diabetic skin ulcer Abandoned US20170258844A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014181463A JP6452107B2 (ja) 2014-09-05 2014-09-05 糖尿病性皮膚潰瘍治療のための多能性幹細胞
JP2014-181463 2014-09-05
PCT/JP2015/067789 WO2016035419A1 (ja) 2014-09-05 2015-06-19 糖尿病性皮膚潰瘍治療のための多能性幹細胞

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2015/067789 A-371-Of-International WO2016035419A1 (ja) 2014-09-05 2015-06-19 糖尿病性皮膚潰瘍治療のための多能性幹細胞

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/288,705 Division US11000552B2 (en) 2014-09-05 2019-02-28 Pluripotent stem cell for treating diabetic skin ulcer

Publications (1)

Publication Number Publication Date
US20170258844A1 true US20170258844A1 (en) 2017-09-14

Family

ID=55439490

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/508,872 Abandoned US20170258844A1 (en) 2014-09-05 2015-06-19 Pluripotent stem cell for treating diabetic skin ulcer
US16/288,705 Active US11000552B2 (en) 2014-09-05 2019-02-28 Pluripotent stem cell for treating diabetic skin ulcer

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/288,705 Active US11000552B2 (en) 2014-09-05 2019-02-28 Pluripotent stem cell for treating diabetic skin ulcer

Country Status (14)

Country Link
US (2) US20170258844A1 (da)
EP (1) EP3189844B1 (da)
JP (1) JP6452107B2 (da)
KR (2) KR20180104196A (da)
CN (1) CN107073041A (da)
AU (1) AU2015310286B2 (da)
CA (1) CA2959957C (da)
DK (1) DK3189844T3 (da)
ES (1) ES2846795T3 (da)
HU (1) HUE052584T2 (da)
PL (1) PL3189844T3 (da)
PT (1) PT3189844T (da)
SG (1) SG11201701788YA (da)
WO (1) WO2016035419A1 (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000552B2 (en) 2014-09-05 2021-05-11 The University Of Tokyo Pluripotent stem cell for treating diabetic skin ulcer

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017303905B2 (en) 2016-07-29 2022-11-10 Life Science Institute, Inc. Prophylactic or therapeutic agent for vascular disorder
JPWO2018235834A1 (ja) * 2017-06-19 2020-04-16 国立大学法人北海道大学 表皮水疱症の治療剤
CN111225676A (zh) * 2017-10-17 2020-06-02 国立大学法人广岛大学 诱导骨软骨修复的多能性干细胞
WO2019191309A1 (en) * 2018-03-27 2019-10-03 Tautona Group Ip Holding Company, L.L.C. Topical and transdermal delivery of an iron chelator to prevent and treat chronic wounds
CN110585242A (zh) * 2019-10-15 2019-12-20 南通大学 多系分化持续应激细胞的应用、治疗糖尿病的药物及其制备方法
KR20210127510A (ko) 2020-04-14 2021-10-22 사회복지법인 삼성생명공익재단 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 당뇨병성 피부질환 예방 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110070647A1 (en) * 2009-07-15 2011-03-24 Mari Dezawa Pluripotent stem cell that can be isolated from body tissue

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530543A (ja) 2004-03-22 2007-11-01 オシリス セラピューティクス，インコーポレイテッド 間葉幹細胞及びその使用法
CN103113463B (zh) 2005-12-13 2015-02-18 国立大学法人京都大学 核重新编程因子
KR20210138808A (ko) * 2006-10-02 2021-11-19 메조블라스트 인터내셔널 에스에이알엘 중간엽 줄기 세포 및 그에 대한 용도
US8835170B2 (en) 2006-10-06 2014-09-16 University Of Virginia Patent Foundation Methods and compositions useful for diabetic wound healing
DK2055308T3 (da) * 2006-10-30 2017-07-17 Genomix Co Ltd Lægemiddel til fremme af funktionel regenerering af beskadiget væv
WO2008100442A1 (en) * 2007-02-09 2008-08-21 Biomet Biologics, Inc. Treatment of tissue defects with a therapeutic composition
BRPI0911513A2 (pt) 2008-04-30 2016-07-12 Genomix Co Ltd métodos e agentes para coleta de células tronco da medula óssea funcionais in vivo com alta eficiência
US9399758B2 (en) * 2009-07-15 2016-07-26 Mari Dezawa SSEA3(+) pluripotent stem cell that can be isolated from body tissue
JP2014133703A (ja) * 2011-03-30 2014-07-24 Clio Inc 生体組織から単離できるｓｓｅａ−３陽性の多能性幹細胞を含む他家移植用細胞治療用組成物
US20130251670A1 (en) * 2011-09-13 2013-09-26 Aidan Products, Inc Treatment of Macular Edema Utilizing Stem Cell and Conditioned Media Thereof
JP2015500810A (ja) * 2011-11-30 2015-01-08 アドバンスド セル テクノロジー、インコーポレイテッド 間葉系間質細胞及びその関連用途
JP2015509508A (ja) * 2012-03-06 2015-03-30 エスシーティアンドビー インコーポレイテッド 胎盤性幹細胞、それを単離するための方法およびその使用
JP2015522257A (ja) * 2012-06-13 2015-08-06 ステムジェント， インコーポレイテッドＳｔｅｍｇｅｎｔ， Ｉｎｃ． 多能性幹細胞を調製する方法
WO2014027474A1 (ja) 2012-08-17 2014-02-20 株式会社Ｃｌｉｏ 心筋梗塞の修復再生を誘導する多能性幹細胞
WO2014133090A1 (ja) * 2013-02-28 2014-09-04 国立大学法人浜松医科大学 脳腫瘍治療のための多能性幹細胞
AU2014221659B2 (en) * 2013-03-01 2018-12-20 Clio, Inc. Pharmaceutical composition including migratory factor for guiding pluripotent stem cells to injury
JP6452107B2 (ja) 2014-09-05 2019-01-16 国立大学法人 東京大学 糖尿病性皮膚潰瘍治療のための多能性幹細胞

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110070647A1 (en) * 2009-07-15 2011-03-24 Mari Dezawa Pluripotent stem cell that can be isolated from body tissue

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000552B2 (en) 2014-09-05 2021-05-11 The University Of Tokyo Pluripotent stem cell for treating diabetic skin ulcer

Also Published As

Publication number Publication date
JP6452107B2 (ja) 2019-01-16
KR102136450B1 (ko) 2020-07-21
CA2959957C (en) 2020-12-15
WO2016035419A1 (ja) 2016-03-10
DK3189844T3 (da) 2021-01-18
JP2016056109A (ja) 2016-04-21
PL3189844T3 (pl) 2021-06-28
EP3189844A1 (en) 2017-07-12
AU2015310286B2 (en) 2018-11-08
CN107073041A (zh) 2017-08-18
HUE052584T2 (hu) 2022-03-28
KR20170055477A (ko) 2017-05-19
KR20180104196A (ko) 2018-09-19
PT3189844T (pt) 2021-02-05
CA2959957A1 (en) 2016-03-10
US20190192574A1 (en) 2019-06-27
EP3189844A4 (en) 2018-05-02
EP3189844B1 (en) 2020-11-18
US11000552B2 (en) 2021-05-11
ES2846795T3 (es) 2021-07-29
SG11201701788YA (en) 2017-06-29
AU2015310286A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
US11000552B2 (en) Pluripotent stem cell for treating diabetic skin ulcer
Li et al. Human amniotic mesenchymal stem cells and their paracrine factors promote wound healing by inhibiting heat stress-induced skin cell apoptosis and enhancing their proliferation through activating PI3K/AKT signaling pathway
Cho et al. Acellular and cellular approaches to improve diabetic wound healing
Lin et al. Evaluation of a multi-layer adipose-derived stem cell sheet in a full-thickness wound healing model
Shi et al. Localization of human adipose-derived stem cells and their effect in repair of diabetic foot ulcers in rats
Azari et al. Effects of transplanted mesenchymal stem cells isolated from Wharton’s jelly of caprine umbilical cord on cutaneous wound healing; histopathological evaluation
Gorecka et al. Induced pluripotent stem cell-derived smooth muscle cells increase angiogenesis and accelerate diabetic wound healing
EP3551748B1 (en) Perinatal tissue derived mesenchymal stem cells: method of preparation and uses thereof
Yang et al. Platelet poor plasma gel combined with amnion improves the therapeutic effects of human umbilical cord‑derived mesenchymal stem cells on wound healing in rats
JP2020172536A (ja) 創傷治癒のための幹細胞
Tracy et al. State of the field: cellular and exosomal therapeutic approaches in vascular regeneration
Nilforoushzadeh et al. Topical spray of Wharton's jelly mesenchymal stem cells derived from umbilical cord accelerates diabetic wound healing
KR20160105363A (ko) 건 또는 인대 손상 치유를 위한 자가 및 동종의 지방유래 중간엽줄기세포 조성물 및 이의 제조방법
Zhou et al. Constructing tissue-engineered dressing membranes with adipose-derived stem cells and acellular dermal matrix for diabetic wound healing: A comparative study of hypoxia-or normoxia-culture modes
KR101617673B1 (ko) 성체줄기세포 및 엘라스틴 유사 폴리펩타이드를 포함하는 상처 치료 촉진용 약학적 조성물
Lai et al. Combination of PDGF-BB and adipose-derived stem cells accelerated wound healing through modulating PTEN/AKT pathway
Mizushima et al. The features of adipose-derived stem cells in patients with inflammatory bowel diseases
Panda et al. Stem cell-based tissue engineering approaches for diabetic foot ulcer: a review from mechanism to clinical trial
JP7213479B2 (ja) 皮膚保護剤
RU2780179C2 (ru) Происходящие из перинатальной ткани мезенхимальные стволовые клетки: способ их получения и применения
Tracy et al. New Developments in Translational Microcirculatory Research: State of the field: cellular and exosomal therapeutic approaches in vascular regeneration
KR20230137808A (ko) 지방 조직 유래 중간엽 줄기세포 및 인간 기질 혈관 분획을 포함하는 혈관신생 촉진용 조성물
Farrokhi Evaluating the therapeutic use of Indoleamine 2, 3-dioxygenase (IDO) expressing allogenic dermal fibroblast populated within an acellular skin substitute as a wound coverage
Al-Fouadi Wound Healing Potential of Human Neonatal Mesenchymal Cells in an Animal Model of Hyperglycemia

Legal Events

Date Code Title Description
AS Assignment

Owner name: TOHOKU UNIVERSITY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YOSHIMURA, KOTARO;KINOSHITA, KAHORI;DEZAWA, MARI;SIGNING DATES FROM 20170315 TO 20170317;REEL/FRAME:043191/0539

Owner name: THE UNIVERSITY OF TOKYO, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YOSHIMURA, KOTARO;KINOSHITA, KAHORI;DEZAWA, MARI;SIGNING DATES FROM 20170315 TO 20170317;REEL/FRAME:043191/0539

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION